Literature DB >> 19837464

Elucidating the elite: mechanisms of control in HIV-1 infection.

Karen A O'Connell1, Justin R Bailey, Joel N Blankson.   

Abstract

In patients with progressive disease, untreated HIV-1 infection is characterized by high viral loads and decreasing CD4(+)T cell counts which lead to opportunistic infection and other AIDS-defining illness. A rare subset of patients termed 'elite controllers' (ECs) maintain control over viremia and often retain normal CD4(+)T cell levels without treatment with antiretroviral drugs. For the most part these patients are infected with replication-competent, fit virus. Factors such as strong, polyfunctional cytotoxic T lymphocyte (CTL) responses and retention of T cell proliferative ability appear to be important in control of HIV-1. Defining what enables ECs to control viral replication will aid in the development of effective vaccine and treatment regimens. This review will discuss differences between ECs and progressors while emphasizing recent findings on the immunological response of ECs to HIV-1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837464     DOI: 10.1016/j.tips.2009.09.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  61 in total

1.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

2.  Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses.

Authors:  Asier Sáez-Cirión; So Youn Shin; Pierre Versmisse; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  Nat Protoc       Date:  2010-05-13       Impact factor: 13.491

3.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 4.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

5.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

6.  Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression.

Authors:  Adam R Hersperger; Jeffrey N Martin; Lucy Y Shin; Prameet M Sheth; Colin M Kovacs; Gabriela L Cosma; George Makedonas; Florencia Pereyra; Bruce D Walker; Rupert Kaul; Steven G Deeks; Michael R Betts
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

Review 7.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

8.  Killing the messenger to maintain control of HIV.

Authors:  Joel N Blankson
Journal:  Nat Med       Date:  2011-08-04       Impact factor: 53.440

9.  Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.

Authors:  Adam M Spivak; Maria Salgado; S Alireza Rabi; Karen A O'Connell; Joel N Blankson
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

10.  HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.

Authors:  Christine M Durand; Karen A O'Connell; Linda G Apuzzo; Susan J Langan; Hejab Imteyaz; Aima A Ahonkhai; Christina M Ceccato; Thomas M Williams; Joseph B Margolick; Joel N Blankson
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.